Shares of Crispr Therapeutics (CRSP) experienced a day of turbulence on Friday following the groundbreaking news of the Food and Drug Administration (FDA) approving the company's gene-editing treatment for sickle cell disease. While CRSP stock initially rallied in anticipation of the announcement, it later plummeted, shedding more than 8% by the end of the trading day.

The FDA's approval signifies a significant milestone for Crispr Therapeutics and its innovative gene-editing technology known as CRISPR. The treatment was co-developed by Vertex Pharmaceuticals (VRTX), further highlighting the collaborative efforts in advancing medical breakthroughs.

Earlier in November, the Crispr treatment received approval from the U.K.'s Medicines and Healthcare products Regulatory Agency for patients aged 12 and older suffering from sickle cell disease or beta thalassemia, both blood-related disorders. This news resulted in a surge in CRSP stock, pushing it up by nearly 50% year to date.

However, on Friday, CRSP stock faced a setback, as it experienced an 8.1% decline, closing at 64.54. Despite this decline, the stock has been trading around a 72 cup-base buy point, indicating potential for future growth.

Meanwhile, VRTX stock, representing Vertex Pharmaceuticals, dipped 1.1% on the same trading day, closing at 350.15, slightly below its 50-day line.

Investors and market analysts are closely watching the developments at Crispr Therapeutics, particularly pertaining to the future impact and success of its gene-editing treatment in combating sickle cell disease. The FDA's approval signifies a significant leap forward in the field of genetic medicine and offers hope for patients suffering from debilitating blood disorders.

As the demand for innovative medical solutions continues to grow, Crispr Therapeutics and Vertex Pharmaceuticals find themselves at the forefront of pioneering treatments that have the potential to transform lives. The volatility observed in CRSP stock following the FDA's approval reflects both the market's anticipation and uncertainty surrounding the commercial viability and long-term success of gene-editing technologies.

While the initial market reaction showed enthusiasm, the subsequent decline in CRSP stock highlights the inherent risks associated with novel medical breakthroughs. Investors and stakeholders alike will be monitoring the progress of Crispr Therapeutics and Vertex Pharmaceuticals as they navigate the complex landscape of gene-editing treatments, aiming to bring new hope and improved healthcare options to patients in need.